This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Questcor Honored As An "Everyday Hero" By NephCure Foundation

Stocks in this article: QCOR

ANAHEIM, Calif., Nov. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the company has been recognized with an "Everyday Hero" award from the NephCure Foundation for its "tireless efforts" to advance science and research in the field of nephrology and to also promote educational efforts related to the treatment of proteinuria in patients with kidney disease who are suffering from nephrotic syndrome.  The NephCure Foundation is a charity organization committed exclusively to supporting research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome, improving treatment and finding a cure.

"Questcor is honored to have received this recognition from NephCure," said Steve Cartt, Chief Operating Officer of Questcor. "We feel strongly about supporting research and educational initiatives that will positively impact patients with kidney disease and the nephrology community as a whole.  Our flagship product, Acthar, is an FDA-approved prescription medication that is used by an increasing number of nephrologists to induce remission of proteinuria in patients who are suffering from certain types of nephrotic syndrome.  We are proud to support the nephrology community through the funding of research, education and other important initiatives."

Henry Brehm, executive director of NephCure, said the organization decided to recognize Questcor because of its support for a patient population that has a significant unmet need.  "Questcor has proven through its actions that it is committed to education, assistance and research that strive to improve the quality of life for patients suffering from nephrotic syndrome, until a cure can be found.  We applaud their dedication and commitment to our community."

Questcor was honored at NephCure's annual "Countdown for a Cure" fundraiser held on November 21 st in New York City.  The event raises money and awareness for its efforts to fund medical research and education programs in the fight against the kidney disease.  Since its inception nine years ago, "Countdown To A Cure" has raised over $3 million for The NephCure Foundation.

About Proteinuria and Nephrotic Syndrome

Proteinuria (excess urinary protein) can be caused by a variety of diseases and disorders of the kidney.  A significant deterioration in kidney function can result in very high levels of proteinuria, a condition associated with nephrotic syndrome. Left untreated, nephrotic syndrome may lead to end stage renal disease, which typically requires life-long dialysis treatments.  Types of kidney disease that can lead to nephrotic syndrome and end-stage renal disease include:

  • Idiopathic Membranous Nephropathy (MN)
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Minimal Change Disease (MCD)
  • Membranoproliferative Glomerulonephritis (MPGN)
  • Lupus Nephritis (LN)
  • IgA Nephropathy (IgA)

These diseases damage the glomeruli, small blood vessels that work as a filtering system in the kidneys. They normally keep substances that a body needs, such as blood proteins (albumin), while filtering wastes and excess water from the blood and passing them into the urine. But because they're damaged, the kidneys' filtering system cannot properly function.  As a result, substances like protein that were previously unable to pass through can now leak or "spill" into a person's urine. This leads to high protein levels in a person's urine, or proteinuria.  Because of this condition, an individual's blood lacks the protein necessary to regulate fluid throughout the body.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs